Showing 4201-4210 of 5771 results for "".
- Hillrom Launches Welch Allyn PanOptic Plus Ophthalmoscopehttps://modernod.com/news/hillrom-launches-digital-physical-assessment-innovations-to-advance-connected-care/2479106/Hillrom announced technological advances to its physical assessment tools with the launch of the new Welch Allyn PanOptic Plus Ophthalmoscope and the Welch Allyn MacroView Plus Otoscope. Examining the structure of the eyes and ears is a critical part of assessing p
- Ocuphire’s APX3330 for Retinal Diseases to be Presented at ARVO 2021https://modernod.com/news/ocuphires-apx3330-for-retinal-diseases-to-be-presented-at-arvo-2021/2479102/Ocuphire Pharma announced that data from preclinical studies and pharmacokinetic modeling of the company’s proprietary APX3330 drug candidate will be presented on Sunday, May 2, 2021 during the Association for Research in Vision and Ophthalmology (ARVO) virtual Annual Meeting, May 1-7, 2021.
- US Patents for Nicox’s Vyzulta (Latanoprostene Bunod) Eligible for Patent Term Extensionhttps://modernod.com/news/us-patents-for-nicoxs-vyzulta-latanoprostene-bunod-eligible-for-patent-term-extension/2479103/Nicox SA announced that the United States Patent and Trademark Office (USPTO) has determined that three U.S. composition of matter patents covering latanoprostene bunod, commercialized as Vyzulta (latanoprostene bunod ophthalmic solution), 0.024%, are eligible for patent term extension, potential
- Johnson & Johnson Vision Receives FDA Clearance and CE Mark for Veritas Vision Systemhttps://modernod.com/news/johnson-johnson-vision-receives-fda-clearance-and-ce-mark-for-next-generation-phacoemulsification-machine-veritas-vision-system/2479100/Johnson & Johnson Vision announced the FDA 510(k) clearance and CE mark of its next-generation phacoemulsification device, the Veritas Vision System. The phaco system features technologies that allow surgeons to guide through any lens density with less surge and more stability. The new system
- Johnson & Johnson Vision Introduces Acuvue Abiliti to Address Myopia in Childrenhttps://modernod.com/news/johnson-johnson-vision-introduces-acuvue-abiliti-to-address-myopia-in-children/2479101/Johnson & Johnson Vision announced the launch of Acuvue Abiliti, a new brand for future products and services aimed at helping parents and eye care providers address the growing prevalence and progression of myopia in children. Abiliti will provide parents and eye care providers with c
- EyeCare Partners Promotes David Clark to Chief Executive Officerhttps://modernod.com/news/eyecare-partners-promotes-david-clark-to-chief-executive-officer/2479099/EyeCare Partners LLC announced the promotion of David A. Clark to chief executive officer, effective immediately. Mr. Clark joined EyeCare Partners as president in July 2020 after 20 years with MEDNAX Inc., where he was most recently ch
- Texas Eye and Cataract Clinic Now Accepting Bitcoin for LASIKhttps://modernod.com/news/texas-eye-and-cataract-clinic-now-accepting-bitcoin-for-lasik-surgery/2479096/Texas Eye and Cataract (TEC) announced that it had begun accepting payments for LASIK procedures via the cryptocurrency Bitcoin. Texas Eye and Cataract said it began accepting Bitcoin to help patients looking for innovative ways to finance their LASIK procedures. “We’ve never b
- Ora Appoints David P. Bingaman, DVM, PhD, in Newly Created Chief Development Officer Positionhttps://modernod.com/news/ora-appoints-david-p-bingaman-dvm-phd-in-newly-created-chief-development-officer-position/2479097/Ora announced that David P. Bingaman, DVM, PhD, D. ACVO has joined the company in a newly created role of Chief Development Officer (CDO). Dr. Bingaman will oversee clinical and nonclinical activities that directly impact Ora’s customers around the world. Ora’s clinical research spans all
- Gyroscope Therapeutics Files Registration Statement for Proposed Initial Public Offering in the United Stateshttps://modernod.com/news/gyroscope-therapeutics-files-registration-statement-for-proposed-initial-public-offering-in-the-united-states/2479087/Gyroscope Therapeutics announced it has filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering (IPO) in the United States. All American Depositary Shares (ADSS) to be sold in the proposed IPO will be
- Aerie Pharmaceuticals Receives Marketing Authorization of Roclanda in Great Britainhttps://modernod.com/news/aerie-pharmaceuticals-receives-marketing-authorisation-of-roclanda-in-great-britain/2479089/Aerie Pharmaceuticals announced that Roclanda 50 micrograms/ml + 200 micrograms/ml eye drops solution (latanoprost + netarsudil) has received marketing authorization from the Medicines and Healthcare Products Regulatory Agency (MHRA) in Great Britain. Roclanda is indicated for the reduction of el